{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:26:19Z","timestamp":1780629979947,"version":"3.54.1"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,2,9]],"date-time":"2012-02-09T00:00:00Z","timestamp":1328745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:p><jats:bold>Objectives:\u2003<\/jats:bold>To determine whether long\u2010term administration of an angiotensin\u2003II type\u20031 receptor antagonist improves morphology and function in obstructed bladders.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold>Male Sprague\u2013Dawley rats underwent surgery to produce bladder outlet obstruction (bladder outlet obstruction group;<jats:italic>n<\/jats:italic>\u2003=\u200332) or sham surgery (sham group;<jats:italic>n<\/jats:italic>\u2003=\u200316). A total of 2\u2003weeks later, 16 bladder outlet obstruction\u2010rats were given the AT1 antagonist, candesartan, subcutaneously (candesartan group) using an osmotic pump for 4\u2003weeks; the remaining bladder outlet obstruction\u2010rats received vehicle (bladder outlet obstruction group). A total of 6\u2003weeks after surgery, we compared continuous cystometry, bladder weight, strip contraction, histology and messenger ribonucleic acid expression of growth factors, nicotinamide adenine dinucleotide phosphate oxidase\u20031 and renin\u2013angiotensin system components among the three groups.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold>Bladder weights markedly increased with bladder outlet obstruction (578\u2003\u00b1\u2003159\u2003mg), and candesartan (344\u2003\u00b1\u2003111\u2003mg) suppressed this increase. Micturition pressure, which was significantly higher with bladder outlet obstruction, was unaffected by candesartan. The shortened micturition interval and decreased micturition volume with bladder outlet obstruction were significantly prolonged and increased by candesartan. Candesartan also significantly decreased residual urine. Histologically, the collagen fiber\u2010to\u2010muscle ratio was significantly increased with bladder outlet obstruction (0.85\u2003\u00b1\u20030.25) compared with the sham group (0.53\u2003\u00b1\u20030.18); this increase was suppressed by candesartan (0.49\u2003\u00b1\u20030.21). The messenger ribonucleic acid expression of heparin\u2010binding epidermal growth factor\u2010like growth factor, transforming growth factor\u2010\u03b21 and nicotinamide adenine dinucleotide phosphate oxidase\u20031 significantly increased with bladder outlet obstruction, but it was significantly reduced by candesartan. Compared with the bladder outlet obstruction group, candesartan increased the maximal contraction of bladder strips for all stimuli except for angiotensin\u2003II.<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold>These findings suggest that bladder angiotensin\u2003II type\u20031 receptors contribute to the pathophysiology of remodeling and dysfunction in obstructed bladder.<\/jats:p>","DOI":"10.1111\/j.1442-2042.2012.02965.x","type":"journal-article","created":{"date-parts":[[2012,2,9]],"date-time":"2012-02-09T17:22:34Z","timestamp":1328808154000},"page":"457-464","source":"Crossref","is-referenced-by-count":11,"title":["Involvement of angiotensin\u2003II type\u20031 receptor on pathological remodeling and dysfunction in obstructed bladder"],"prefix":"10.1111","volume":"19","author":[{"given":"Ken","family":"Aikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takio","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homare","family":"Shiomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Akaihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,9]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6777(2000)19:5<609::AID-NAU7>3.0.CO;2-H"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.12.023"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20984"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1998.275.5.C1247"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.2000.279.4.C1155"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.34.5.1112"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01751.x"},{"key":"e_1_2_8_9_2","first-page":"R1186","article-title":"Angiotensin II and bladder obstruction in the rat: influence on hypertrophic growth and contractility","volume":"271","author":"Persson K","year":"1996","journal-title":"Am. J. Physiol."},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64397-0"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000220403.61493.18"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(00)00286-7"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.10.223"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.10.244"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09445.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700282"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.86.5.494"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2005.12.049"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00886-4"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.06.124"},{"issue":"1","key":"e_1_2_8_21_2","first-page":"s19","article-title":"Medical management of lower urinary tract symptoms","volume":"11","author":"Laborde EE","year":"2009","journal-title":"Rev. Urol."},{"key":"e_1_2_8_22_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-3565(25)38306-0","article-title":"Pharmacological profile of a highly potent and long\u2010acting angiotensin II receptor antagonist, 2\u2010Ethoxy\u20101\u2010[[2\u2032\u2010(1H\u2010tetrazol\u20105\u2010yl)biphenyl\u20104\u2010yl]methyl]\u20101H\u2010benzimidazole\u20107\u2010carboxylic acid (CV\u201011974), and its prodrug, \u00b1)\u20101\u2010(cyclohexyloxycarbonyloxy)\u2010ethyl 2\u2010Ethoxy\u20101\u2010[[2\u2032\u2010(1H\u2010tetrazol\u20105\u2010yl)biphenyl\u20104\u2010yl]methyl]\u20101H\u2010benzimidazole\u20107\u2010carboxylate (TCV\u2010116)","volume":"266","author":"Shibouta Y","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000066129.12106.E2"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.03.015"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701240"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1137"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-2042.2012.02965.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-2042.2012.02965.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:55:49Z","timestamp":1742446549000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-2042.2012.02965.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1442-2042.2012.02965.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-2042.2012.02965.x","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,9]]}}}